The “direct-acting antiviral era” for hepatitis C has been a novel step forward in medicine with several regimens providing cure rates of 95% or higher and many available as secondary treatments for patients whose initial treatment failed. With this highly curative option, researchers have focused on evaluating opportunities to use hepatitis-C infected organs to increase the transplant donor pool.

Healio Gastroenterology and Liver Disease presents eight reports on data showing safety and efficacy of transplanting HCV-positive organs into HCV-negative recipients, including both preventative therapy and posttransplant treatment for heart, kidney, and liver transplantations.